Our results pave the way to further studies to evaluate CD5 PNA treatment’s feasibility in combination with chemotherapy as an appealing approach for more effective therapeutic strategies in B-CLL. The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.